Pleural Fluid Eosinophilia: A Possible Adverse Event of Interleukin-17 Inhibition

Acta Derm Venereol. 2019 Nov 1;99(12):1174-1175. doi: 10.2340/00015555-3311.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Dermatologic Agents / adverse effects*
  • Drug Substitution
  • Eosinophilia / chemically induced*
  • Eosinophilia / diagnosis
  • Humans
  • Infliximab / therapeutic use
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukin-17 / immunology
  • Male
  • Pleural Effusion / chemically induced*
  • Pleural Effusion / diagnosis
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Receptors, Interleukin-17 / antagonists & inhibitors*
  • Receptors, Interleukin-17 / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • IL17A protein, human
  • IL17RA protein, human
  • Interleukin-17
  • Receptors, Interleukin-17
  • brodalumab
  • Infliximab
  • secukinumab